RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research.

13 Jan 2011

Study highlights important clinical implications of miR-503 in diabetes-associated vascular complications

New research has found one of the smallest entities in the human genome, micro-RNA, could increase the risk of limb amputation in diabetic patients who have poor blood flow.

13 Jan 2011

Scientists introduce DNA directly into cell nucleus using protein nanodisks

One of the challenges of gene therapy - a set of methodologies aimed at treating several nucleic acid diseases - is to assure that this material arrives directly to the nucleus of the cell without losing a substantial amount along the way and without producing any undesired side effects. With this aim, scientists experiment with the use of different types of vectors, molecules capable of transporting genetic material to the correct place.

12 Jan 2011

Illumina announces acquisition of Epicentre Biotechnologies

Illumina, today announced that it has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications.

From Illumina, Inc. 12 Jan 2011

Life Technologies announces new DNA sequencing portfolio for lab research

Life Technologies Corporation today announced a series of new product innovations across the company's DNA sequencing portfolio. To date, most sequencing technologies have primarily addressed the needs of researchers in the highest throughput laboratories, limiting widespread accessibility of these powerful next-generation sequencing technologies.

12 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

Nationwide Children's Hospital was awarded $11.5 million from the National Cancer Institute late last year to continue its role as one of two Biospecimen Core Resources for The Cancer Genome Atlas.

11 Jan 2011

All fat cells not the same

All fat cells are not the same - a fact that has implications in the understanding and treatment of type 2 diabetes and obesity, said researchers from Baylor College of Medicine (www.bcm.edu) in a report that appears in the current issue of the Journal of Cell Biology (http://www.jcb.rupress.org/).

10 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

Illumina announces next generation of iSelect custom genotyping products

Illumina, Inc. today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs.

From Illumina, Inc. 10 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Hologic announces acquisition of Interlace Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN Surgical Products division.

From Hologic, Inc. 7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

6 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

RNA News and Research

Further Reading

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Study highlights important clinical implications of miR-503 in diabetes-associated vascular complications

Scientists introduce DNA directly into cell nucleus using protein nanodisks

Illumina announces acquisition of Epicentre Biotechnologies

Life Technologies announces new DNA sequencing portfolio for lab research

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

QIAGEN to acquire minority stake in Alacris Theranostics

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

All fat cells not the same

Research suggests novel therapeutic approach for Huntington's Disease

Illumina announces next generation of iSelect custom genotyping products

New mechanisms of resistance to chemotherapy among leukemia patients

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Hologic announces acquisition of Interlace Medical

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Mutated TDP-43 can cause neurons to die: Study

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News